Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
– Initiation of Phase 1 clinical trial marks Entrada’s transition into a clinical company –…
Richard Roths Media Announces $52 Million Dollar Investment Approval to Expand its AI-Driven Marketing Systems
Four Inc. Secures Spot on Washington Technology’s Top 100 Government Contractors List for 11th Consecutive Year
Tat Hong Equipment Service Co., Ltd. Announces 2025/26 Annual Results